A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2020.00393
Abstract: Anemia is a complication of chronic kidney disease (CKD), primarily due to insufficient secretion of erythropoietin (EPO) by the kidney. Erythropoiesis-stimulating agents (ESAs) are used to treat anemia associated with chronic kidney disease. A poor… read more here.
Keywords: novel choice; induced anemia; inflammation; choice correct ... See more keywords